Login / Signup

Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair.

Farah BalloutHeng LuNadeem BhatLei ChenDunfa PengZheng ChenXi Steven ChenXiaodian SunSilvia GiordanoSimona CorsoAlexander I ZaikaOliver G McDonaldAlan S LivingstoneWael El-Rifai
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Our results identify SMAD3 as a promising therapeutic target for future combination strategies for the treatment of patients with EAC.
Keyphrases
  • dna repair
  • epithelial mesenchymal transition
  • dna damage
  • transforming growth factor
  • dna damage response
  • squamous cell carcinoma
  • current status
  • cancer therapy
  • smoking cessation